PA2G4 and neuroblastoma: Similar to a MYCN-dependent neuroblastoma model44, the genetic and chemical disruption of the PA2G4-MYC interface with the small molecule inhibitor WS647 altered AML cell proliferation, supporting an oncogenic role of PA2G4 in 3q26 AML.